A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
What will 2020 hold for marijuana acceptance, employee misclassification, formularies, and AI?
An analysis of 1.5 million claims found early physical therapy lowers odds of opioid use by 14%.
Testing positive for marijuana use could one day no longer prohibit employment.
With a flurry of opioid developments lately, what does the big picture look like?
Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.
Does the active ingredient in magic mushrooms have a future in mental health?
Phase 3 studies are underway, and current research sees potential for MDMA in psychotherapy.
A recent meta-analysis of over 100 trials and studies found lavender to significantly reduce anxiety levels.
A biosimilar to Humira is approved, the FDA Fast Tracks a PTSD drug, and more.
Understand how prices are set for medical equipment and services, and how to scrutinize those costs.
According to the CWCI, reduced opioid utilization from 2010-2017 saved $6.5 billion in California comp costs.
Beyond compensability, Minnesota considers rules for evaluation, treatment planning, acceptable psychotherapies, and more.
Workers’ comp publications cover Healthesystems content surrounding aging physicians, successful return-to-work programs, and more.
A previous gastrointestinal drug recall expands, while a new recall for an anxiety drug is issued.
The guideline covers a wide range of relevant topics, including pain, dosing, dangerous co-prescribing, comorbidities, and more.
Shortly after California made strides on employee classification for gig economy jobs, New Jersey and New York have taken action.
The Society of Actuaries published a report that claims the economic burden of the opioid epidemic was $631 billion from 2015-2018.
Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.
PwC explores how social factors impact chronic health conditions.
This reclassification will entitle millions of workers to benefits previously withheld, including workers’ comp.
Join Healthesystems at booth #1922, at an educational presentation, or by taking our industry survey with Risk & Insurance.
NKTR-181 (loxicodegol) was to receive an approval decision by August 29th, but a reevaluation of opioid policy has resulted in a delay.
Healthesystems’ clinical leaders speak to mitigation strategies to reduce workplace injuries stemming from fatigue.
The utilization of opioids, compounds, and physician-dispensed medications have significantly decreased.
Proposed changes to who can grow and research marijuana will soon be available for public commentary.
An Oklahoma judge found the drug maker to be partially responsible for the harm of the opioid epidemic.
Healthesystems’ Chief Medical Officer explores trends impacting workers’ comp, including patient engagement, population health, and more.
Nine generic versions of Lyrica (pregabalin) have been approved for the treatment of five different medical conditions.
Sandy Shtab has been recognized for making significant contributions to the workers’ comp industry.
Looking at over 29 billion private health claims, this study found that claim lines related to telehealth rose 624% from 2014-2018.
While many states report fewer opioid prescriptions, MME levels vary more significantly by state.
NCCI estimates that a 25-75% reduction in motor vehicle accidents in workers’ comp could save $1-4 billion, creating interest in self-driving cars.
Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.
While the utilization of opioids and other problematic drugs decreased, similar drops were seen in states without closed formularies.
Stephanie Arkelian has been recognized as a talented young professional making a positive impact on the workers’ comp industry.
Beyond exceptions for safety or federal positions, employers cannot refuse employment for testing positive for marijuana in pre-employment drug screenings.
A new study builds upon earlier research with a larger, more up-to-date dataset, finding a reversal in trends.
Visit Healthesystems in booth #909 and learn how we’re making waves in workers’ comp, and how we hope to benefit coastal cleanups for the “Coast to Coast” theme.
Orphengesic Forte has received a decision date of August 14, 2019.
How services like Lyft and Uber can amplify injured worker transportation programs to improve claims outcomes.
Though they’re only needed for special cases in workers’ comp, anticancer medications can easily exceed $10,000 per monthly fill.
In a call for public comment, the FDA believes that reducing excess opioid supplies can lower opioid misuse, abuse, and overdose.
The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.
Healthesystems partnered with Risk & Insurance magazine to survey 500+ work comp professionals on their top challenges, trends, successes, and more.
Combining all three drugs can reduce claim closure rates to 58.3%, with average claim costs of $94,000.
Florida enacted a law to cover 21 different cancers, while other states like Montana, Maryland, and Virginia have recently passed similar laws.
Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.
New changes to REMS safety programs will require stronger treatment documentation and oversight.
Patient engagement can lead to better health outcomes, but not all engagement strategies are equally effective.
The workforce is aging, getting younger, and gaining more women, all at once. What does that mean for claims management?
Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.
Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.
Despite having little clinical impact, topical creams continue to be utilized widely in workers’ comp.
Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.
Can special implants in the brain override paralysis? The FDA believes one day they could.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.
